Celularity (CELU) Change in Receivables (2020 - 2025)
Celularity (CELU) posted quarterly Change in Receivables of -$548000.0 for Q4 2025, down 110.91% year-over-year from $5.0 million in Q4 2024, and up 87.94% quarter-over-quarter from -$4.5 million in Q3 2025.
Celularity (CELU) Change in Receivables (2020 - 2025) Analysis & Trends
Celularity (CELU) has reported Change in Receivables for 6 consecutive years, with -$548000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Receivables fell 110.91% year-over-year to -$548000.0; the TTM figure through Dec 2025 stood at -$7.6 million (down 290.3% YoY), while the FY2025 annual figure was -$7.6 million, down 290.3% from the prior year.
- Change in Receivables rose to -$548000.0 in Q4 2025 per CELU's latest filing, from -$4.5 million in the prior quarter.
- Across five years, Change in Receivables topped out at $6.7 million in Q4 2023 and bottomed at -$4.8 million in Q3 2024.
- Historically, Change in Receivables has averaged $436850.0 across 5 years, with a median of $469500.0 in 2021.
- Annual changes were most pronounced in 2021 — Change in Receivables surged 717.65% — and 2025, when it tumbled 1883.33%.
- Celularity's Change in Receivables stood at $1.2 million in 2021, then slipped by 22.42% to $896000.0 in 2022, then surged by 648.77% to $6.7 million in 2023, then slipped by 25.15% to $5.0 million in 2024, then sank by 110.91% to -$548000.0 in 2025.
- Business Quant data shows CELU's Change in Receivables at -$548000.0 in Q4 2025, -$4.5 million in Q3 2025, and -$3.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.71 Bn | 130.86 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.60 Bn | 77.60 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.82 Bn | 59.63 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.92 Bn | 52.79 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.88 Bn | 36.78 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.46 Bn | 28.15 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 27.96 Bn | 9.57 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Celularity | 20.73 Mn | 14.56 Mn | -3.27 Mn | -548,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -548,000.00 |
| Dec 31, 2025 | -548,000.00 |
| Sep 30, 2025 | -4.55 Mn |
| Sep 30, 2025 | -4.55 Mn |
| Jun 30, 2025 | -3.81 Mn |
| Jun 30, 2025 | -3.81 Mn |
| Mar 31, 2025 | 1.35 Mn |
| Mar 31, 2025 | 1.35 Mn |
| Dec 31, 2024 | 5.02 Mn |
| Dec 31, 2024 | 5.02 Mn |
| Sep 30, 2024 | -4.79 Mn |
| Sep 30, 2024 | -4.79 Mn |
| Jun 30, 2024 | -192,000.00 |
| Jun 30, 2024 | -192,000.00 |
| Mar 31, 2024 | 3.92 Mn |
| Mar 31, 2024 | 3.92 Mn |
| Dec 31, 2023 | 6.71 Mn |
| Dec 31, 2023 | 6.71 Mn |
| Sep 30, 2023 | 1.38 Mn |
| Sep 30, 2023 | 1.38 Mn |